Corgentech, BMS Announce Results From Edifoligide Trial for CABG Failure

Corgentech and Bristol-Myers Squibb (BMS) have announced top-line results from PREVENT IV, a Phase III clinical trial evaluating the use of edifoligide (E2F Decoy), an investigational product, to prevent vein graft failure following coronary artery bypass graft (CABG) surgery.

Treatment with E2F Decoy failed to meet the trial's primary and secondary endpoints. E2F Decoy was generally well-tolerated in the 3,014-patient trial.

The complete data from the PREVENT IV trial will be presented in future scientific publications and presentations by the study's clinical investigators.

Corgentech and BMS have an agreement to jointly develop and commercialize Corgentech's E2F Decoy. BMS has advised Corgentech that it will be terminating the collaboration consistent with the agreement.